Andrea Small-Howard, Phd, Mba
AeroLeads people directory · profile

Andrea Small-Howard, Phd, Mba Email & Phone Number

CEO and Chairman of the Board at GB Sciences, Inc
Location: Los Angeles Metropolitan Area, United States, United States 18 work roles 3 schools
2 work emails found @gbsciences.com 4 phones found area 808, 714, 844, and 866 LinkedIn matched
✓ Verified May 2026 4 data sources Profile completeness 100%

Contact Signals · 2 work emails · 4 phones

Work email a****@gbsciences.com
Direct phone (808) ***-****
LinkedIn Profile matched
3 free lookups remaining · No credit card
Current company
Role
CEO and Chairman of the Board
Location
Los Angeles Metropolitan Area, United States, United States
Company size

Who is Andrea Small-Howard, Phd, Mba? Overview

A concise factual answer block for searchers comparing this professional profile.

Quick answer

Andrea Small-Howard, Phd, Mba is listed as CEO and Chairman of the Board at GB Sciences, Inc, a company with 22 employees, based in Los Angeles Metropolitan Area, United States, United States. AeroLeads shows a work email signal at gbsciences.com, phone signal with area code 808, 714, 844, 866, and a matched LinkedIn profile for Andrea Small-Howard, Phd, Mba.

Andrea Small-Howard, Phd, Mba previously worked as Chief Executive Officer & Chairman of the Board at Gb Sciences, Inc and Chief Science Officer at Gb Sciences, Inc. Andrea Small-Howard, Phd, Mba holds Mba, Executive Mba, Class Xxv from Usc Marshall School Of Business.

Company email context

Email format at GB Sciences, Inc

This section adds company-level context without repeating Andrea Small-Howard, Phd, Mba's masked contact details.

{first}@gbsciences.com
92% confidence

AeroLeads found 2 current-domain work email signals for Andrea Small-Howard, Phd, Mba. Compare company email patterns before reaching out.

Profile bio

About Andrea Small-Howard, Phd, Mba

Dr. Andrea Small-Howard has 20+ years of executive experience in the biopharma industry. She has shaped corporate strategies and messaging, led partnering efforts, and raised capital. In addition, she has supervised research & development, manufacturing, and quality control in global divisions. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration ("US FDA"), and orchestrated commercial licensing deals.Currently, Dr. Small-Howard leverages her broad biopharmaceutical industry knowledge as the Chief Executive Officer, Chief Science Officer, and Chairman of the Board of Directors at GB Sciences, Inc. (OTCQB:GBLX), and she serves on the Board of Directors of their wholly-owned Canadian subsidiary, GBS Global Biopharma, Inc. Dr. Small-Howard is the architect of a strategic vision at Gb Sciences/GbS Global Biopharma to make safe, effective, standardized cannabinoid medicines available to patients where their use can be supported with rigorous evidence. To achieve standardization in their cannabinoid-containing, optimized therapeutic mixtures, the Company is using synthetic cannabinoids produced under current Good Manufacturing Practices (cGMP), which are identical in both structure and function to the homologous plant cannabinoids.Dr. Small-Howard envisages bringing more phytomedicines to market through GB Sciences’ innovative AI-based drug discovery engine and biopharmaceutical drug development programs for disease-specific indications. Dr. Small-Howard researched cannabinoids for over 20 years, leading a project group dedicated to the study of cannabinoids in the immune system as an NIH-funded post-doctoral fellow. In this work she published one of the earliest studies of cannabinoid impacts on pro-inflammatory immunocytes. More recently, she has contributed to published studies on consumer protection issues surrounding ‘medicinal’ Cannabis chemovars in Nevada, co-authored scholarly reviews on cannabinoids in heart disease and Parkinson’s Disease, co-authored mechanistic studies on cannabinoid and terpene regulation of ion channels, and co-authored an innovative study demonstrating the utility of nanoparticles as delivery vehicles for Cannabis-derived therapeutic compounds.

Listed skills include Biotechnology, Lifesciences, Molecular Biology, Biochemistry, and 46 others.

Current workplace

Andrea Small-Howard, Phd, Mba's current company

Company context helps verify the profile and gives searchers a useful next step.

GB Sciences, Inc
Gb Sciences, Inc
CEO and Chairman of the Board
Los Angeles, CA, US
Website
Employees
22
AeroLeads page
18 roles

Andrea Small-Howard, Phd, Mba work experience

A career timeline built from the work history available for this profile.

Chief Executive Officer & Chairman Of The Board

Current

Las Vegas, Nevada, US

GB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures.

Jul 2024 - Present

Chief Science Officer

Current

Las Vegas, Nevada, US

GB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech company developing patented formulations of plant-inspired, minimum essential mixtures for the prescription drug market.

Jun 2014 - Present

Board Member

Current

Las Vegas, Nevada, US

GB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech developing plant-inspired minimal essential mixtures (MEM) for the prescription drug market.

Jun 2014 - Present

President

Las Vegas, Nevada, US

GB Sciences, Inc. (OTCQB: GBLX) is a plant-inspired biopharma drug development company whose goal is to create patented formulations of plant-inspired, Minimal Essential Mixtures (MEM) for the prescription drug market that target a variety of medical conditions. The active ingredients in our MEM are synthetic homologues identical to the original plant.

Jun 2021 - Jul 2024

Chief Science Officer & Director

Current

GbS Global Biopharma (GbS) Inc. is a plant-based research and biopharmaceutical development company located in Ottawa, Canada. GbS Global Biopharma's proprietary drug discovery platform generates Active Pharmaceutical Ingredient (API) mixtures for a variety of medical indications. The company currently has Rx programs in late pre-clinical and their lead.

Mar 2019 - Present

Board Member

Chicago, Illinois, US

The Center for Healthcare Innovation is a non-profit, non-partisan, and independent organization committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation, particularly in the biotechnology, medical device, nanotechnology, and pharmaceutical sectors. The CHI.

Jan 2012 - Feb 2016

President

International Biotechnology Solutions

International Biotechnology Solutions creates customized, cost-effective commercialization solutions for viable yet abandoned biopharma products. Based on our understanding that the paradigm by which biotechnology and pharmaceutical products reach the market has fundamentally changed, we explore new avenues to bring healthcare products to market in regions.

Jul 2011 - Nov 2015

Board Member

The Ceremax Investment Group was established by members of the USC EMBA Class XXV to pool its financial and intellectual resources to identify investment opportunities. Ceremax will capitalize on the collective experiences and pool of contacts of its members to source, underwrite, and manage these investment opportunities. Additionally, Ceremax will.

Jun 2011 - Mar 2013

Vice President, Scientific Oversight

Radient Pharmaceuticals Corporation
  • Provided oversight for global product development in multiple international business divisions
  • Authored and/or attained 12 patents & 3 trademarks on proprietary cancer tests, cancer (gene) therapies, cosmeceuticals, and animal models
  • Achieved numerous regulatory approvals for cancer tests, cancer therapies, pharmaceuticals, and cosmeceutical products with US FDA, Health Canada, Korean FDA, China SFDA, Taiwanese Ministry of Health, Indian Ministry.
  • Initiated and/or nurtured 5 international, collaborative, cancer research trial programs with universities and hospitals studying colon, lung, and pancreatic cancer; as well as general cancer screening programs that.
  • Championed Elleuxe®/Goodnak® cosmeceutical line  Provided oversight for formulations, safety & effectiveness testing, regulatory strategy  Led branding committee and created marketing materials with external agencies.
  • Led and participated in internal and US FDA, CDPH, CE Mark/ISO 13485, and CMDR audits
Nov 2008 - Jul 2011

Director, Research, Development, Scientific Oversight

Amdl, Inc.
  • Championed DR-70® colorectal cancer test that accounts for 100% of domestic sales  Patented invention, performed clinical trials, obtained US FDA, KFDA, and CMDR approvals  Created commercialization strategy, advised.
  • Designed commercialization strategy for in-licensed cervical cancer test, MyHPV Kit®  Developed technical product file in Korea with original manufacturer, created US prototype  Sourced US raw materials, hired.
  • Represented company and promoted cancer tests at international cancer meetings
  • Advised CEO on additional licensed technologies through due diligence research
Jul 2007 - Nov 2008

Manager Of Research & Development

Amdl, Inc.
  • Led medical device product development for colon, lung, pancreatic and general cancer tests with an annual budget of approximately $2.4 million USD
  • Represented company regulatory filings directly with US FDA agency
  • Managed intellectual property portfolio
  • Achieved 28% decrease in production error rate through continuous process improvement program in manufacturing
Feb 2006 - Jul 2007

Research Assistant Professor

Honolulu, Hawaii, US

Responsibilities: in charge of research division devoted to the study of selenoprotein biosynthesis and role of selenoproteins in protection from oxidative damage.Projects: identifying supramolecular complexes responsible for selenocysteine incorporation; demonstrating nucleo-cytoplasmic shuttling of selenium incorporation cofactors, defining the role of.

Jun 2004 - Jan 2006

Postdoctoral Research Fellow

Honolulu, HI, US

Principal Investigator: Helen Turner, Ph.DProjects: the effects of cannabinoids on immune cells; oncogenic signaling by cigarette smoke condensates (CSC) in human mast cells; defining the calcium store operated transcriptome in mast cells

Sep 2001 - Jun 2004

Graduate Researcher/Teaching Assistant

Los Angeles, CA, US

Performed independent research; served as a teaching assistant in biochemistry (won teaching awards); molecular biology, and immunology. Gave guest lectures: 1) in the freshman biology class on plant physiology and 2) histology class on reproductive tissues and morphological/functional distinctions among gastrointestinal tissues.

Aug 1992 - May 1999

Research Project Supervisor

Los Angeles, CA, US

Principal Investigator: John S. Stephens, Ph. DOccidental College, Los Angeles, CA 90041The overall goal of the research project was to determine if thermal warming from the hydroelectric plant in King Harbor was having an effect on the local fauna, especially as it might have an impact on reef fish. Led monthly ichthyoplankton sample collections.

Sep 1988 - May 1991

Research Assistant

Los Angeles, CA, US

Supervisor: Gary Jordan, M.A.Occidental College, Los Angeles, CA 90041Monitoring effects of sport fishing on fish stocks at the Salton Sea, California.

Aug 1987 - Aug 1988
3 education records

Andrea Small-Howard, Phd, Mba education

Mba, Executive Mba, Class Xxv

Usc Marshall School Of Business

Ph.D., Biochemistry, Molecular Biology, Immunology

University Of Southern California

Ab, Biology, Philosophy

Occidental College
FAQ

Frequently asked questions about Andrea Small-Howard, Phd, Mba

Quick answers generated from the profile data available on this page.

What company does Andrea Small-Howard, Phd, Mba work for?

Andrea Small-Howard, Phd, Mba works for GB Sciences, Inc.

What is Andrea Small-Howard, Phd, Mba's role at GB Sciences, Inc?

Andrea Small-Howard, Phd, Mba is listed as CEO and Chairman of the Board at GB Sciences, Inc.

What is Andrea Small-Howard, Phd, Mba's email address?

AeroLeads has found 2 work email signals at @gbsciences.com for Andrea Small-Howard, Phd, Mba at GB Sciences, Inc.

What is Andrea Small-Howard, Phd, Mba's phone number?

AeroLeads has found 4 phone signal(s) with area code 808, 714, 844, 866 for Andrea Small-Howard, Phd, Mba at GB Sciences, Inc.

Where is Andrea Small-Howard, Phd, Mba based?

Andrea Small-Howard, Phd, Mba is based in Los Angeles Metropolitan Area, United States, United States while working with GB Sciences, Inc.

What companies has Andrea Small-Howard, Phd, Mba worked for?

Andrea Small-Howard, Phd, Mba has worked for Gb Sciences, Inc, Gbs Global Biopharma, Inc., Center For Healthcare Innovation, International Biotechnology Solutions, and Ceremax Investment Corporation.

How can I contact Andrea Small-Howard, Phd, Mba?

You can use AeroLeads to view verified contact signals for Andrea Small-Howard, Phd, Mba at GB Sciences, Inc, including work email, phone, and LinkedIn data when available.

What schools did Andrea Small-Howard, Phd, Mba attend?

Andrea Small-Howard, Phd, Mba holds Mba, Executive Mba, Class Xxv from Usc Marshall School Of Business.

What skills is Andrea Small-Howard, Phd, Mba known for?

Andrea Small-Howard, Phd, Mba is listed with skills including Biotechnology, Lifesciences, Molecular Biology, Biochemistry, Pharmaceutical Industry, Commercialization, Biopharmaceuticals, and Immunology.

Find 750M verified contacts

Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.